Analysis
Intuitive Surgical (ISRG) faces significant headwinds from U.S. tariffs introduced in 2025, primarily affecting its cost of revenues and gross margins. The company's exposure stems from importing endoscopes from Germany and raw materials and sub-assemblies from China. While a significant majority of its instruments and accessories are manufactured in Mexicali, Mexico, these products have remained largely exempt from U.S. import tariffs to date under USMCA.
In FY2025, the company reported that tariffs and other trade measures increased its cost of revenues by approximately $63M, representing an estimated 65bps headwind to its pro forma gross margin. This impact was slightly lower than initial mid-year estimates of 100bps, partly due to the timing of implementation and inventory capitalization. However, the company expects this pressure to intensify in FY2026 as the full-year effect of the tariff framework is realized and older inventory is exhausted.
For FY2026, management has provided guidance reflecting an anticipated tariff impact of 1.2% of net revenue, plus or minus 10bps. This represents an incremental ~50bps headwind compared to FY2025. Based on the company's 2026 procedure growth guidance of 13% to 15%, the total cost impact for FY2026 is estimated to reach between $125M and $150M.
Beyond direct cost increases, trade tensions have impacted the company's competitive positioning in China. Intuitive reported intensified competition from domestic robotic-assisted surgical system manufacturers and a lower win ratio for provincial tenders, which increasingly favor local suppliers. While these dynamics have affected system placement timing and win rates in the region, the company continues to leverage its local manufacturing capabilities and joint venture structure to mitigate long-term risks.
Mitigation strategies include production and manufacturing optimization and potential long-term operational actions. However, management noted that such measures are not expected to have a significant beneficial impact in the immediate term, with the primary focus remaining on scaling manufacturing and managing supply chain reliability amid evolving trade requirements.
Data
($M, except percentages)
| Metric | FY2025A | FY2026E |
|---|---|---|
| Estimated Gross Tariff Cost | $63 | $125 – $150 |
| Tariff Impact on Net Revenue (%) | 0.6% | 1.1% – 1.3% |
| Pro Forma Gross Margin Impact (bps) | 65 | 110 – 130 |
Note: FY2026E estimates are based on company guidance of 1.2% ± 10bps of net revenue and estimated revenue growth in line with 13%–15% procedure growth guidance. Source: Company filings, Marvin Labs
Financial Impact
- Cost Impact (Historic): $63M
- Cost Impact (Forward-Looking): $125M–$150M
Sources
In 2025, tariffs and other trade measures have increased our cost of revenues by approximately $63.0 million. Based on the announced and implemented global tariffs as of the date of this report, and assuming such tariffs remain in place, we expect our cost of revenues driven by tariffs and other trade measures to continue to increase in 2026.
In 2026, we expect our pro forma gross profit margin to be within a range of 67% and 68% of net revenue. This year, we forecast an impact from tariffs of 1.2% of net revenue, ±10 basis points. ... I would highlight again, we have 120 basis points of tariffs reflected in the 2026 guidance. That was about 65 basis points in 2025.
The updated range for expected non-GAAP gross profit margin reflects the company’s estimates of the impact from tariffs that are in effect or have been announced with both a firm percentage and implementation date as of the time of this press release and assumes such tariffs remain in place.